In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013

Diagnostic Microbiology and Infectious Disease

Volumn 80, Issue 4, 2014, Pages 311-315

  Karlowsky, J A ^a   Walkty, A J ^a   Baxter, M R ^a   Adam, H J ^a   Zhanel, G G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

MRSA; Oritavancin; Skin and soft tissue infection

Indexed keywords

DAPTOMYCIN; LINEZOLID; ORITAVANCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CANADA; DRUG ACTIVITY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GRAM POSITIVE INFECTION; HOSPITAL LABORATORY; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CANADA; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LABORATORIES, HOSPITAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 84919458034     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.09.003     Document Type: Article

References (18)

1. Arhin F.F., Sarmiento I., Parr T.R., Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009, 64:868-870.
2. Arhin F.F., Draghi D.C., Pillar C.M., Moeck G., Sahm D.F. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. Int J Antimicrob Agents 2012, 40:562-563.
3. Arhin F.F., Sarmiento I., Moeck G. In vitro activities of oritavancin and comparators against methicillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. Int J Antimicrob Agents 2014, 44:65-68.
4. Bordon J.M., Master R.N., Clark R.B., Karlowsky J.A., Klotchko A., Duvvuri P., et al. Methicillin-resistant Staphylococcus aureus resistance to non-β-lactam antimicrobials in the United States from 1996 to 2008. Diagn Microbiol Infect Dis 2010, 67:395-398.
5. Boyd D.A., Kibsey P., Roscoe D., Mulvey M.R. Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon. J Antimicrob Chemother 2004, 54:680-683.
6. Chambers H.F. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med 2014, 370:2238-2239.
7. Clinical and Laboratory Standards Institute (CLSI) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Ninth Edition: Approved Standard M07-A9 2012, CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fourth Informational Supplement. Document M100-S24 2014, CLSI, Wayne, PA.
9. Corey G.R., Kabler H., Mehra P., Gupta S., Overcash J.S., Porwal A., et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014, 370:2180-2190.
10. Golding G.R., Campbell J.L., Spreitzer D.J., Veyhl J., Surynicz K., Simor A., et al. Canadian Nosocomial Infection Surveillance Program. A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing. Can J Infect Dis Med Microbiol 2008, 19:273-281.
11. McDonald R.R., Antonishyn N.A., Hansen T., Snook L.A., Nagle E., Mulvey M.R., et al. Development of a triplex real-time PCR assay for detection of Panton-Valentine Leukocidin toxin genes in clinical isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43:6147-6149.
12. Mendes R.E., Farrell D.J., Sader H.S., Jones R.N. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012, 54(Suppl 3):S203-S213.
13. Mendes R.E., Sader H.S., Flamm R.K., Farrell D.J., Jones R.N. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother 2014, 58:2921-2924.
14. Mendes R.E., Sader H.S., Flamm R.K., Jones R.N. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. J Antimicrob Chemother 2014, 69:1579-1581.
15. Moellering R.C., Ferraro M.J. Introduction: solving the clinical problem of vancomycin resistance. Clin Infect Dis 2012, 54(Suppl. 3):S201-S202.
16. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
17. Nichol K.A., Adam H.J., Roscoe D.L., Golding G.R., Lagace-Wiens P.R.S., Hoban D.J., et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. J Antimicrob Chemother 2013, 68(Suppl 1):i47-i55.
18. Zhanel G.G., Schweizer F., Karlowsky J.A. Oritavancin: mechanism of action. Clin Infect Dis 2012, 54(Suppl 3):S214-S219.